Across TCGA pan-cancer cohorts, RPL23P8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL23P8 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL23P8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23P8 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, CESC, and PRAD are the cancer types where RPL23P8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
CESC	DFS	Median	All	0.191	0.823	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.545	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RPL23P8 tumor-vs-normal RNA expression · all RPL23P8 data types